Tags : MRD Status

AbbVie to Deploy Adaptive’s clonoSEQ Assay to Assess MRD Status

Shots: AbbVie in collaboration with Adaptive evaluate depth and duration of response to venetoclax and measure minimal residual disease (MRD) status in MM treated patients utilizing Adaptive’s next-generation sequencing (NGS)-based clonoSEQ assay The partnership encourages the development & regulatory approval of venetoclax in MM and the increasing use of clonoSEQ in drug development as a […]Read More